NCT06589440 2026-01-15
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05205330 2025-10-29
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Rottapharm Biotech
Phase 1/2 Active not recruiting
NCT03104699 2025-07-30
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
Phase 1/2 Completed
NCT05377528 2025-04-30
Study of AGEN1571 in Participants With Advanced Solid Tumors
Agenus Inc.
Phase 1 Completed
NCT03894215 2025-02-20
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Agenus Inc.
Phase 2 Active not recruiting
NCT03860272 2025-02-06
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT06782555 2025-01-21
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
Phase 1/2 Recruiting
NCT05033132 2024-03-28
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Agenus Inc.
Phase 2 Withdrawn
NCT03495882 2023-07-05
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
Agenus Inc.
Phase 1/2 Completed
NCT05561491 2023-06-22
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Targovax ASA
Phase 2 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn